TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Update

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) saw a significant decline in short interest in May. As of May 31st, there was short interest totalling 32,700 shares, a decline of 70.0% from the May 15th total of 109,000 shares. Based on an average daily volume of 48,800 shares, the days-to-cover ratio is currently 0.7 days. Currently, 0.2% of the company's stock are short sold.

Insiders Place Their Bets

In other news, insider Richard Marshak sold 6,597 shares of the company's stock in a transaction on Monday, May 19th. The shares were sold at an average price of $5.18, for a total value of $34,172.46. Following the completion of the transaction, the insider now directly owns 69,101 shares in the company, valued at approximately $357,943.18. This represents a 8.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 16,125 shares of company stock worth $83,528 over the last quarter. 27.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Geode Capital Management LLC boosted its stake in TriSalus Life Sciences by 1.9% during the fourth quarter. Geode Capital Management LLC now owns 204,137 shares of the company's stock valued at $1,023,000 after buying an additional 3,710 shares in the last quarter. Northern Trust Corp raised its holdings in shares of TriSalus Life Sciences by 22.7% in the 4th quarter. Northern Trust Corp now owns 32,112 shares of the company's stock worth $161,000 after purchasing an additional 5,936 shares in the last quarter. Charles Schwab Investment Management Inc. acquired a new stake in TriSalus Life Sciences during the first quarter valued at approximately $55,000. Renaissance Technologies LLC bought a new stake in TriSalus Life Sciences during the fourth quarter worth approximately $67,000. Finally, Connective Capital Management LLC acquired a new position in TriSalus Life Sciences in the fourth quarter worth approximately $140,000. 2.58% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group reissued a "buy" rating and issued a $11.00 price target on shares of TriSalus Life Sciences in a report on Friday, March 28th. Six analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $10.75.

TriSalus Life Sciences Stock Up 6.2%

Shares of NASDAQ:TLSI traded up $0.32 on Monday, reaching $5.51. 27,907 shares of the company's stock were exchanged, compared to its average volume of 42,731. The firm has a market capitalization of $208.49 million, a price-to-earnings ratio of -2.21 and a beta of 0.47. TriSalus Life Sciences has a fifty-two week low of $3.50 and a fifty-two week high of $6.14. The business's 50-day moving average is $5.40 and its two-hundred day moving average is $5.18.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($0.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.13). The company had revenue of $9.17 million for the quarter, compared to analyst estimates of $9.04 million. During the same period in the previous year, the company posted ($0.60) earnings per share. Analysts predict that TriSalus Life Sciences will post -1.55 earnings per share for the current fiscal year.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.